

The impact of Positron Emission Tomography (PET) imaging in staging potentially surgically resectable non-small cell lung cancers: a prospective, multicentre randomised clinical trial

Submission date 05/11/2007	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 05/11/2007	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 13/07/2009	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Mark N. Levine

Contact details
Ontario Clinical Oncology Group (OCOG)
711 Concession St
Hamilton, Ontario
Canada
L8V 1C3
mlevine@mcmaster.ca

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00136890

Protocol serial number
MCT-78777

Study information

Scientific Title

Acronym

ELPET Trial

Study objectives

In patients with clinical stage I - IIIA Non-Small Cell Lung Cancer (NSCLC) who are potential candidates for surgery with curative intent, to determine whether preoperative whole body PET or PET-Computed Tomography (CT) in conjunction with cranial imaging identifies more precisely those patients with occult mediastinal or extrathoracic metastatic disease, thereby sparing them from undergoing stage-inappropriate therapies, when compared to conventional preoperative staging (CT liver/adrenals, total body bone scan, CT with contrast or Magnetic Resonance Imaging [MRI] with gadolinium of the brain).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Research Ethics Board of University Health Networks, Toronto, Ontario, Canada approved on the 12th March 2004 (ref: 04-0006-C).

Study design

Multicentre, two arm, randomised parallel trial exploring diagnostic strategy

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Stage I, II, IIIA Non-small Cell Lung Cancer

Interventions

PET Imaging versus Conventional Staging.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

The proportion of patients in the whole body PET/PET-CT plus brain CT/MRI arm versus the conventional staging arm who are correctly upstaged to stage IIIB or IV disease prior to planned treatment, thereby sparing patients from stage-inappropriate therapy (true positives), to be measured at any time during the first 2 years of the study.

Key secondary outcome(s))

To be measured any time during the first 2 years of the study:

1. The proportion of patients in each investigational arm that were erroneously understaged and were thereby subject to potentially stage-inappropriate therapy (false negatives), either because they were eventually shown to have pathologic stage III (A or B) disease at mediastinoscopy prior to planned thoracotomy or on lymph node sampling at thoracotomy, or because they developed local recurrence or distant metastases within two years of thoracotomy (pathologic stage IV)
2. For each investigational arm, the overall survival in patients with Stage I-IIIa NSCLC who undergo surgery with curative intent
3. The prognostic ability of the PET Standard Uptake Value (SUV) to predict overall survival in patients with clinical stage I-IIIa NSCLC
4. The sensitivity and specificity of PET/PET-CT in the staging of the mediastinum, when compared to lymph node sampling at thoracotomy
5. The cost-effectiveness of staging with PET versus conventional staging

Completion date

31/07/2011

Eligibility

Key inclusion criteria

1. Histological or cytological proof of NSCLC
2. Stage I, II, or IIIa NSCLC based upon clinical staging
3. The primary lesion appears technically appropriate for surgical resection, based on information from the Chest X-Ray (CXR) and CT thorax
4. Male or female NSCLC patients, 18 years and older

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Poor pulmonary function precluding radical surgery (inadequate pulmonary reserve for radical surgery) with predicted post-resection Forced Expiratory Volume in One second (FEV1) less than 0.8 l or less than 40% predicted, and Diffusing capacity of the Lung for Carbon Monoxide (DLCO) less than 40 % predicted
2. Poor performance status (Eastern Cooperative Oncology Group [ECOG] grade 3 - 4)
3. Significant concurrent medical problems (e.g. uncontrolled diabetes, active cardiac problems, significant chronic obstructive pulmonary disease) making the patient unfit for surgery
4. Pregnant or lactating females
5. Unable to lie supine for imaging with PET
6. Patients with previously treated cancer other than nonmelanotic skin cancer or carcinoma in situ of the cervix, unless disease-free for 5 years or greater
7. Patients who, at the time of the initial evaluation, have already undergone a whole body PET /PET-CT, CT brain, MRI brain, total body bone scan or mediastinoscopy within 8 weeks prior to randomisation will be excluded. However, patients who have had a CT scan of the thorax with abdomen are not excluded
8. Failure to provide informed consent

Date of first enrolment

01/07/2004

Date of final enrolment

31/07/2011

Locations

Countries of recruitment

Canada

Study participating centre

Ontario Clinical Oncology Group (OCOG)

Hamilton, Ontario

Canada

L8V 1C3

Sponsor information

Organisation

McMaster University (Canada)

ROR

<https://ror.org/02fa3aq29>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-78777)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	18/08/2009		Yes	No